PMCB
PharmaCyte Biotech, Inc.Company Information
- Company Name
- PharmaCyte Biotech, Inc.
- CIK
- CIK0001157075
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- PMCB: Nasdaq
- Fiscal Year End
- April 30
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- PMCB
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-01-07
- Last sale
- —
- Shares purchased (TTM)
- 60,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 747,046
- Shares outstanding
- 10,735,649
- Ownership
- 6.96%
Earnings Market Reaction
- Filing date
- 2026-09-14
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 | 2024-01-31 | 2023-10-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 18 | 19 | 20 | 15 | 13 | 15 | 16 | 21 | 33 | 50 | 61 | 73 | ||||||
| Marketable Securities Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | - | - | ||||||
| Dividends Receivable | - | 0 | - | - | - | 0 | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 31 | 37 | 21 | 23 | 19 | 22 | 17 | 21 | 33 | 50 | 62 | 74 | ||||||
| Equity Method Investments | - | - | - | - | - | - | - | - | - | 0 | 2 | 2 | ||||||
Other Assets Noncurrent | ||||||||||||||||||
| Intangible Assets Net Excluding Goodwill | - | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 4 | ||||||
| Investments And Other Noncurrent Assets | - | - | 22 | 21 | 20 | 22 | 19 | 25 | 29 | 0 | - | - | ||||||
| Other Assets | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Investments | - | 0 | - | - | - | 22 | - | - | - | - | - | - | ||||||
| Other Assets Noncurrent | - | 0 | - | - | - | 0 | - | - | - | - | - | - | ||||||
Other Assets | ||||||||||||||||||
| Accounts And Notes Receivable Net | - | - | - | - | - | - | 3 | - | - | - | - | - | ||||||
| Assets Noncurrent | 6 | 9 | 35 | 33 | 26 | 33 | 27 | 34 | 37 | 9 | 10 | 5 | ||||||
| Assets | 37 | 47 | 56 | 56 | 45 | 55 | 44 | 55 | 70 | 60 | 71 | 79 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | ||||||
| Accrued Liabilities Current | 0 | 1 | 0 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Dividends Payable Current | 0 | 0 | 0 | 0 | - | 0 | 0 | 4 | 6 | 6 | 6 | 4 | ||||||
| Liabilities Current | 1 | 1 | 2 | 2 | 1 | 3 | 1 | 5 | 7 | 7 | 8 | 5 | ||||||
| Other Accrued Liabilities Noncurrent | - | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | - | ||||||
| Derivative Liabilities Noncurrent | 0 | 1 | 1 | 2 | - | 0 | 0 | 0 | 1 | 2 | 3 | 4 | ||||||
| Other Liabilities | 6 | 11 | 15 | 18 | 0 | 0 | 2 | 7 | 10 | 13 | 15 | 16 | ||||||
| Liabilities | 7 | 12 | 16 | 19 | 2 | 3 | 4 | 12 | 17 | 20 | 22 | 21 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | - | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 182 | 183 | 183 | 181 | 182 | 181 | 181 | 181 | 183 | 185 | 189 | 194 | ||||||
| Retained Earnings Accumulated Deficit | -109 | -104 | -100 | -101 | -93 | -85 | -97 | -94 | -92 | -116 | -117 | -116 | ||||||
| Treasury Stock Common Value | -45 | -45 | -45 | -45 | -45 | -45 | -44 | -44 | -43 | -42 | -41 | -40 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Stockholders Equity | 28 | 33 | 38 | 35 | 44 | 52 | 40 | 43 | 48 | 28 | 31 | 37 | ||||||
| Liabilities And Stockholders Equity | 37 | 47 | 56 | 56 | 45 | 55 | 44 | 55 | 70 | 60 | 71 | 79 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | - | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | - | - | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | - | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Par Or Stated Value Per Share | - | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Issued | 26 | 26 | 26 | - | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | ||||||
| Shares Outstanding | 11 | 11 | 11 | - | 7 | 7 | 7 | 7 | 8 | 8 | 9 | 9 | ||||||
| Treasury Stock Common Shares | 15 | 15 | - | - | - | 15 | 15 | 15 | 14 | 14 | 13 | 13 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialPharmaCyte Biotech, Inc. (PMCB) — SEC Financial Statements & Analysis
PharmaCyte Biotech, Inc. (PMCB) is a biological products, (no diagnostic substances) company, incorporated in NV. PharmaCyte Biotech, Inc. trades on Nasdaq as: PMCB. PharmaCyte Biotech, Inc. (PMCB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-07-31, filed with the SEC on 2026-09-14. Based on that filing, PharmaCyte Biotech, Inc. carries a market cap of $6.18M, a P/E ratio of -0.38x, a P/B ratio of 0.22x, an enterprise value of $-11.56M, and an EV/EBITDA multiple of 1.65x. On profitability, it posts a Return on Equity (ROE) of -45.42%, a Return on Assets (ROA) of -39.47%, and a Return on Invested Capital (ROIC) of -34.90%. Per share, it reports EPS of $-1.50, diluted EPS of $-1.50, free cash flow per share of $-0.37, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 91.77% year-over-year and EPS growth of 21.39% year-over-year. On the balance sheet, it maintains a current ratio of 40.30x, a quick ratio of 40.25x, working capital of $30.21M, a debt-to-equity ratio of 0.25x, a debt ratio of 0.19, free cash flow of $-3.94M (TTM), and net debt of $-17.74M. Figures sourced from SEC EDGAR.
- Market Cap
- $6.18M
- P/E TTM
- -0.38x
- EPS TTM
- $-1.50
- P/B TTM
- 0.22x
- ROE TTM
- -45.42%
- ROA TTM
- -39.47%
- Debt To Equity
- 0.25x
- Free Cash Flow TTM
- $-3.94M
Data as of 2026-07-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is PharmaCyte Biotech, Inc. in?
PharmaCyte Biotech, Inc. (PMCB) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does PMCB trade on?
PharmaCyte Biotech, Inc. (PMCB) trades on the Nasdaq.
Where is PharmaCyte Biotech, Inc. incorporated?
PharmaCyte Biotech, Inc. is incorporated in NV.
When was PharmaCyte Biotech, Inc. (PMCB)'s most recent SEC filing?
PharmaCyte Biotech, Inc. (PMCB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-07-31, filed with the SEC on 2026-09-14.
What is PMCB's market cap?
PharmaCyte Biotech, Inc. (PMCB) has a market capitalization of $6.18M as of 2026-07-31.
What is PMCB's EPS (earnings per share)?
PharmaCyte Biotech, Inc. (PMCB)'s trailing twelve month EPS is $-1.50 as of 2026-07-31.
What is PMCB's ROE (return on equity)?
PharmaCyte Biotech, Inc. (PMCB)'s trailing twelve month Return on Equity (ROE) is -45.42% as of 2026-07-31.
What is PMCB's ROA (return on assets)?
PharmaCyte Biotech, Inc. (PMCB)'s trailing twelve month Return on Assets (ROA) is -39.47% as of 2026-07-31.
What is PMCB's ROIC (return on invested capital)?
PharmaCyte Biotech, Inc. (PMCB)'s trailing twelve month Return on Invested Capital (ROIC) is -34.90% as of 2026-07-31.
What is PMCB's EV/EBITDA?
PharmaCyte Biotech, Inc. (PMCB)'s trailing twelve month EV/EBITDA is 1.65x as of 2026-07-31.